Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
November 13, 2024 08:06 ET
|
Organovo, Inc.
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel...
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
July 16, 2024 08:05 ET
|
Organovo, Inc.
Organovo presented on the Company’s near and long-term outlook, operational plans, at the Jones Trading Healthcare Conference in Encinitas, CA.
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
May 21, 2024 08:05 ET
|
Organovo, Inc.
Poster presented at DDW2024 demonstrating the potential of the Company’s clinical-stage compound, FXR314, in combination with tofacitinib for treating IBD.
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
January 09, 2024 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (IBD),...
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
August 23, 2023 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with...
Organovo Announces FXR Program
March 21, 2023 08:05 ET
|
Organovo, Inc.
SAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated...
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates
November 15, 2022 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology (3D biology) company focused on delivering scientific and medical breakthroughs using...
Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 08:20 ET
|
Organovo, Inc.
SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate...
Organovo Announces Postponement of Annual Meeting of Stockholders
September 06, 2022 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate...
Organovo Achieves 3D Tissue Model for Crohn’s Disease
May 17, 2022 08:05 ET
|
Organovo, Inc.
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional (3D) biology company focused on delivering scientific and medical breakthroughs using novel...